ProEthic Pharmaceuticals, Inc. Announces Positive Phase III Clinical Trial Results For Fast-Acting Migraine Product Candidate

MONTGOMERY, Ala.--(BUSINESS WIRE)--ProEthic Pharmaceuticals, Inc., a privately funded specialty pharmaceutical company that acquires, develops, licenses and markets niche prescription products, announced today successful Phase III clinical trial results for PRO-513, its product candidate for the treatment of migraine headaches. These findings will serve as the basis for a New Drug Application (NDA) for PRO-513, expected to be filed with the U.S. Food and Drug Administration in early 2007.
MORE ON THIS TOPIC